{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T23:50:41Z","timestamp":1767311441013,"version":"3.48.0"},"publisher-location":"Cham","reference-count":50,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032034014","type":"print"},{"value":"9783032034021","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-03402-1_37","type":"book-chapter","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T23:48:10Z","timestamp":1767311290000},"page":"357-363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiviral Drug Design: Past, Presence, and Future"],"prefix":"10.1007","author":[{"given":"Eleni","family":"Papakonstantinou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Chrousos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Vlachakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"4","key":"37_CR1","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.idc.2019.08.002","volume":"33","author":"DA Asogun","year":"2019","unstructured":"Asogun DA, Gunther S, Akpede GO, Ihekweazu C, Zumla A (2019) Lassa fever: epidemiology, clinical features, diagnosis, management and prevention. Infect Dis Clin N Am 33(4):933\u2013951. https:\/\/doi.org\/10.1016\/j.idc.2019.08.002","journal-title":"Infect Dis Clin N Am"},{"issue":"3","key":"37_CR2","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/0006-291x(89)92756-3","volume":"165","author":"M Baba","year":"1989","unstructured":"Baba M, Tanaka H, De Clercq E, Pauwels R, Balzarini J, Schols D et al (1989) Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun 165(3):1375\u20131381. https:\/\/doi.org\/10.1016\/0006-291x(89)92756-3","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"37_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.antiviral.2003.08.016","volume":"60","author":"R Bartenschlager","year":"2003","unstructured":"Bartenschlager R, Kaul A, Sparacio S (2003) Replication of the hepatitis C virus in cell culture. Antivir Res 60(2):91\u2013102. https:\/\/doi.org\/10.1016\/j.antiviral.2003.08.016","journal-title":"Antivir Res"},{"issue":"2","key":"37_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1525-1470.2005.22208.x","volume":"22","author":"KL Berggren","year":"2005","unstructured":"Berggren KL, Tharp M, Boyer KM (2005) Vaccine-associated \"wild-type\" measles. Pediatr Dermatol 22(2):130\u2013132. https:\/\/doi.org\/10.1111\/j.1525-1470.2005.22208.x","journal-title":"Pediatr Dermatol"},{"issue":"18","key":"37_CR5","doi-asserted-by":"publisher","first-page":"9875","DOI":"10.1128\/JVI.00980-12","volume":"86","author":"M Bienkowska-Haba","year":"2012","unstructured":"Bienkowska-Haba M, Williams C, Kim SM, Garcea RL, Sapp M (2012) Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2\/DNA complex following virus entry. J Virol 86(18):9875\u20139887. https:\/\/doi.org\/10.1128\/JVI.00980-12","journal-title":"J Virol"},{"key":"37_CR6","doi-asserted-by":"publisher","unstructured":"Bryan-Marrugo OL, Ramos-Jim\u00e9nez J, Barrera-Salda\u00f1a H, Rojas-Mart\u00ednez A, Vidaltamayo R, Rivas-Estilla AM (2015) History and progress of antiviral drugs: from acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C. Medicina Universitaria. https:\/\/doi.org\/10.1016\/j.rmu.2015.05.003","DOI":"10.1016\/j.rmu.2015.05.003"},{"issue":"31","key":"37_CR7","doi-asserted-by":"publisher","first-page":"7356","DOI":"10.1021\/bi9008837","volume":"48","author":"SD Cady","year":"2009","unstructured":"Cady SD, Luo W, Hu F, Hong M (2009) Structure and function of the influenza A M2 proton channel. Biochemistry 48(31):7356\u20137364. https:\/\/doi.org\/10.1021\/bi9008837","journal-title":"Biochemistry"},{"key":"37_CR8","volume-title":"Viral meningitis","author":"RM Cantu","year":"2022","unstructured":"Cantu RM, J, M. D. (2022) Viral meningitis. StatPearls, Treasure Island (FL)"},{"issue":"22","key":"37_CR9","doi-asserted-by":"publisher","first-page":"12111","DOI":"10.1128\/JVI.00560-07","volume":"81","author":"KO Chang","year":"2007","unstructured":"Chang KO, George DW (2007) Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells. J Virol 81(22):12111\u201312118. https:\/\/doi.org\/10.1128\/JVI.00560-07","journal-title":"J Virol"},{"issue":"6","key":"37_CR10","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1128\/AAC.00016-14","volume":"58","author":"U Chatterji","year":"2014","unstructured":"Chatterji U, Garcia-Rivera JA, Baugh J, Gawlik K, Wong KA, Zhong W et al (2014) The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance. Antimicrob Agents Chemother 58(6):3327\u20133334. https:\/\/doi.org\/10.1128\/AAC.00016-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"37_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","volume":"18","author":"GBDLRI Collaborators","year":"2018","unstructured":"Collaborators GBDLRI (2018) Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 18(11):1191\u20131210. https:\/\/doi.org\/10.1016\/S1473-3099(18)30310-4","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"37_CR12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1128\/CMR.10.4.674","volume":"10","author":"E De Clercq","year":"1997","unstructured":"De Clercq E (1997) In search of a selective antiviral chemotherapy. Clin Microbiol Rev 10(4):674\u2013693. https:\/\/doi.org\/10.1128\/CMR.10.4.674","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"37_CR13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1128\/CMR.16.4.569-596.2003","volume":"16","author":"E De Clercq","year":"2003","unstructured":"De Clercq E (2003) Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 16(4):569\u2013596. https:\/\/doi.org\/10.1128\/CMR.16.4.569-596.2003","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"37_CR14","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nrmicro975","volume":"2","author":"E De Clercq","year":"2004","unstructured":"De Clercq E (2004) Antivirals and antiviral strategies. Nat Rev Microbiol 2(9):704\u2013720. https:\/\/doi.org\/10.1038\/nrmicro975","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"37_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.antiviral.2005.05.001","volume":"67","author":"E De Clercq","year":"2005","unstructured":"De Clercq E (2005) Antiviral drug discovery and development: where chemistry meets with biomedicine. Antivir Res 67(2):56\u201375. https:\/\/doi.org\/10.1016\/j.antiviral.2005.05.001","journal-title":"Antivir Res"},{"issue":"1","key":"37_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2006.10.006","volume":"75","author":"E De Clercq","year":"2007","unstructured":"De Clercq E (2007) The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antivir Res 75(1):1\u201313. https:\/\/doi.org\/10.1016\/j.antiviral.2006.10.006","journal-title":"Antivir Res"},{"issue":"6087","key":"37_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/323464a0","volume":"323","author":"E De Clercq","year":"1986","unstructured":"De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC (1986) A novel selective broad-spectrum anti-DNA virus agent. Nature 323(6087):464\u2013467. https:\/\/doi.org\/10.1038\/323464a0","journal-title":"Nature"},{"issue":"3","key":"37_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"E De Clercq","year":"2016","unstructured":"De Clercq E, Li G (2016) Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 29(3):695\u2013747. https:\/\/doi.org\/10.1128\/CMR.00102-15","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"37_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/jmv.20911","volume":"79","author":"E Ernst","year":"2007","unstructured":"Ernst E, Schonig K, Bugert JJ, Blaker H, Pfaff E, Stremmel W, Encke J (2007) Generation of inducible hepatitis C virus transgenic mouse lines. J Med Virol 79(8):1103\u20131112. https:\/\/doi.org\/10.1002\/jmv.20911","journal-title":"J Med Virol"},{"key":"37_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3308","volume":"348","author":"ER Feeney","year":"2014","unstructured":"Feeney ER, Chung RT (2014) Antiviral treatment of hepatitis C. BMJ 348:g3308. https:\/\/doi.org\/10.1136\/bmj.g3308","journal-title":"BMJ"},{"key":"37_CR21","doi-asserted-by":"publisher","unstructured":"Franco MA, Greenberg HB (2012) Rotaviruses, noroviruses, and other gastrointestinal viruses. Goldman\u2019s Cecil Med 2144\u20132147. https:\/\/doi.org\/10.1016\/B978-1-4377-1604-7.00388-2","DOI":"10.1016\/B978-1-4377-1604-7.00388-2"},{"issue":"2","key":"37_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/jdds.jdds_23_21","volume":"25","author":"S Himed","year":"2021","unstructured":"Himed S, Muddasani S, Fleischer A (2021) Epidemiology of viral skin disease: an increased burden in childhood and a correlation with atopic dermatitis and gross domestic product. Journal of Dermatology and Dermatologic Surgery 25(2):65\u201369. https:\/\/doi.org\/10.4103\/jdds.jdds_23_21","journal-title":"Journal of Dermatology and Dermatologic Surgery"},{"key":"37_CR23","unstructured":"IHME (2019a) Lower respiratory infections\u2014level 3 cause. From Institute of Health Metrics and Evaluation. https:\/\/www.healthdata.org"},{"key":"37_CR24","unstructured":"IHME (2019b) Upper respiratory infections\u2014level 3 cause. From Institute of Health Metrics and Evaluation. https:\/\/www.healthdata.org"},{"issue":"3","key":"37_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3350\/kjhep.2010.16.3.263","volume":"16","author":"JY Jang","year":"2010","unstructured":"Jang JY, Chung RT (2010) New treatments for chronic hepatitis C. Korean J Hepatol 16(3):263\u2013277. https:\/\/doi.org\/10.3350\/kjhep.2010.16.3.263","journal-title":"Korean J Hepatol"},{"issue":"2","key":"37_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1365-3156.1996.tb00036.x","volume":"1","author":"R Kaminsky","year":"1996","unstructured":"Kaminsky R, Schmid C, Grether Y, Holy A, DeClercq E, Naesens L, Brun R (1996) (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]: a purine analogue with trypanocidal activity in vitro and in vivo. Trop Med Int Health 1(2):255\u2013263. https:\/\/doi.org\/10.1111\/j.1365-3156.1996.tb00036.x","journal-title":"Trop Med Int Health"},{"key":"37_CR27","doi-asserted-by":"publisher","unstructured":"Kelsey, M. C., Mitchell, C. A., Griffin, M., Spencer, R. C., & Emmerson, A. M. (2000). Prevalence of lower respiratory tract infections in hospitalized patients in the United Kingdom and Eire--results from the Second National Prevalence Survey. J Hosp Infect, 46(1), 12\u201322. doi:https:\/\/doi.org\/10.1053\/jhin.2000.0775","DOI":"10.1053\/jhin.2000.0775"},{"key":"37_CR28","doi-asserted-by":"publisher","unstructured":"Kerantzas CA, Jacobs WR Jr (2017) Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application. mBio 8(2). https:\/\/doi.org\/10.1128\/mBio.01586-16","DOI":"10.1128\/mBio.01586-16"},{"key":"37_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4661","volume":"351","author":"SA Kularatne","year":"2015","unstructured":"Kularatne SA (2015) Dengue fever. BMJ 351:h4661. https:\/\/doi.org\/10.1136\/bmj.h4661","journal-title":"BMJ"},{"key":"37_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114485","volume":"185","author":"G Li","year":"2021","unstructured":"Li G, Xu M, Yue T, Gu W, Tan L (2021) Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr Erik De Clercq. Biochem Pharmacol 185:114485. https:\/\/doi.org\/10.1016\/j.bcp.2021.114485","journal-title":"Biochem Pharmacol"},{"issue":"5424","key":"37_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1126\/science.285.5424.110","volume":"285","author":"V Lohmann","year":"1999","unstructured":"Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285(5424):110\u2013113. https:\/\/doi.org\/10.1126\/science.285.5424.110","journal-title":"Science"},{"issue":"6257","key":"37_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/343470a0","volume":"343","author":"R Pauwels","year":"1990","unstructured":"Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ et al (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343(6257):470\u2013474. https:\/\/doi.org\/10.1038\/343470a0","journal-title":"Nature"},{"issue":"6","key":"37_CR33","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.3892\/mmr.2014.2076","volume":"9","author":"J Peng","year":"2014","unstructured":"Peng J, Zhang D, Ma Y, Wang G, Guo Z, Lu J (2014) Protective effect of fluvastatin on influenza virus infection. Mol Med Rep 9(6):2221\u20132226. https:\/\/doi.org\/10.3892\/mmr.2014.2076","journal-title":"Mol Med Rep"},{"issue":"8","key":"37_CR34","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1128\/JVI.79.8.4991-4999.2005","volume":"79","author":"JD Reeves","year":"2005","unstructured":"Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW (2005) Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 79(8):4991\u20134999. https:\/\/doi.org\/10.1128\/JVI.79.8.4991-4999.2005","journal-title":"J Virol"},{"issue":"4953","key":"37_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1126\/science.2183354","volume":"248","author":"NA Roberts","year":"1990","unstructured":"Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB et al (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248(4953):358\u2013361. https:\/\/doi.org\/10.1126\/science.2183354","journal-title":"Science"},{"issue":"6706","key":"37_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/23974","volume":"396","author":"PB Rosenthal","year":"1998","unstructured":"Rosenthal PB, Zhang X, Formanowski F, Fitz W, Wong CH, Meier-Ewert H et al (1998) Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus. Nature 396(6706):92\u201396. https:\/\/doi.org\/10.1038\/23974","journal-title":"Nature"},{"issue":"5","key":"37_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jecm.2013.08.001","volume":"5","author":"H Sadanari","year":"2013","unstructured":"Sadanari H, Murayama T, Zheng X, Yamada R, Matsubara K, Yoshida H, Takahashi T (2013) Inhibitory effects of statins on expression of immediate\u2013early 1 protein of human cytomegalovirus in virus-infected cells. J Exp Clin Med 5(5):187\u2013193. https:\/\/doi.org\/10.1016\/j.jecm.2013.08.001","journal-title":"J Exp Clin Med"},{"issue":"3","key":"37_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0","volume":"7","author":"S Safrin","year":"1997","unstructured":"Safrin S, Cherrington J, Jaffe HS (1997) Clinical uses of cidofovir. Rev Med Virol 7(3):145\u2013156. https:\/\/doi.org\/10.1002\/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0","journal-title":"Rev Med Virol"},{"issue":"2","key":"37_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/13596535211067598","volume":"27","author":"U Schmitz","year":"2022","unstructured":"Schmitz U, Swaminathan S (2022) Discovery and development of oseltamivir at Gilead Sciences. Antivir Ther 27(2):13596535211067598. https:\/\/doi.org\/10.1177\/13596535211067598","journal-title":"Antivir Ther"},{"issue":"2","key":"37_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s0166-3542(97)00065-x","volume":"37","author":"RW Sidwell","year":"1998","unstructured":"Sidwell RW, Huffman JH, Barnard DL, Bailey KW, Wong MH, Morrison A et al (1998) Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antivir Res 37(2):107\u2013120. https:\/\/doi.org\/10.1016\/s0166-3542(97)00065-x","journal-title":"Antivir Res"},{"issue":"3","key":"37_CR41","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1128\/jvi.76.3.1391-1399.2002","volume":"76","author":"M Takeda","year":"2002","unstructured":"Takeda M, Pekosz A, Shuck K, Pinto LH, Lamb RA (2002) Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol 76(3):1391\u20131399. https:\/\/doi.org\/10.1128\/jvi.76.3.1391-1399.2002","journal-title":"J Virol"},{"issue":"1","key":"37_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ja.2017.115","volume":"71","author":"N Takizawa","year":"2018","unstructured":"Takizawa N, Yamasaki M (2018) Current landscape and future prospects of antiviral drugs derived from microbial products. J Antibiot 71(1):45\u201352. https:\/\/doi.org\/10.1038\/ja.2017.115","journal-title":"J Antibiot"},{"issue":"3","key":"37_CR43","first-page":"218","volume":"3","author":"HS Te","year":"2007","unstructured":"Te HS, Randall G, Jensen DM (2007) Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol (N Y) 3(3):218\u2013225","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"37_CR44","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/B978-0-12-411492-0.00034-1","volume-title":"Synthesis of best-seller drugs","author":"R Vardanyan","year":"2016","unstructured":"Vardanyan R, Hruby V (2016) Chapter 34 - antiviral drugs. In: Vardanyan R, Hruby V (eds) Synthesis of best-seller drugs. Academic, Boston, pp 687\u2013736"},{"issue":"12","key":"37_CR45","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nrd2400","volume":"6","author":"M von Itzstein","year":"2007","unstructured":"von Itzstein M (2007) The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6(12):967\u2013974. https:\/\/doi.org\/10.1038\/nrd2400","journal-title":"Nat Rev Drug Discov"},{"issue":"7594","key":"37_CR46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V et al (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531(7594):381\u2013385. https:\/\/doi.org\/10.1038\/nature17180","journal-title":"Nature"},{"issue":"7496","key":"37_CR47","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature13027","volume":"508","author":"TK Warren","year":"2014","unstructured":"Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA et al (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508(7496):402\u2013405. https:\/\/doi.org\/10.1038\/nature13027","journal-title":"Nature"},{"issue":"22","key":"37_CR48","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJM197605272942201","volume":"294","author":"RJ Whitley","year":"1976","unstructured":"Whitley RJ, Ch\u2019ien LT, Dolin R, Galasso GJ, Alford CA Jr (1976) Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study. N Engl J Med 294(22):1193\u20131199. https:\/\/doi.org\/10.1056\/NEJM197605272942201","journal-title":"N Engl J Med"},{"key":"37_CR49","unstructured":"WHO (2022) Poliomyelitis. Retrieved from https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/poliomyelitis"},{"issue":"10049","key":"37_CR50","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(16)31018-2","volume":"388","author":"SZ Wiktor","year":"2016","unstructured":"Wiktor SZ, Hutin YJ (2016) The global burden of viral hepatitis: better estimates to guide hepatitis elimination efforts. Lancet 388(10049):1030\u20131031. https:\/\/doi.org\/10.1016\/S0140-6736(16)31018-2","journal-title":"Lancet"}],"container-title":["Advances in Experimental Medicine and Biology","GeNeDIS 2024"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-03402-1_37","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T23:48:12Z","timestamp":1767311292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-03402-1_37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032034014","9783032034021"],"references-count":50,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-03402-1_37","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"2 January 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"GeNeDIS","order":1,"name":"conference_acronym","label":"Conference Acronym","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"International\u00a0Genomics, Neuroscience, Therapeutics and Data\u00a0Innovation\u00a0Summit","order":2,"name":"conference_name","label":"Conference Name","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Athens","order":3,"name":"conference_city","label":"Conference City","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Greece","order":4,"name":"conference_country","label":"Conference Country","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"2024","order":5,"name":"conference_year","label":"Conference Year","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"17 October 2024","order":7,"name":"conference_start_date","label":"Conference Start Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"20 October 2024","order":8,"name":"conference_end_date","label":"Conference End Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"genedis-12024","order":10,"name":"conference_id","label":"Conference ID","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"https:\/\/easychair.org\/cfp\/GeNeDis2024","order":11,"name":"conference_url","label":"Conference URL","group":{"name":"ConferenceInfo","label":"Conference Information"}}]}}